ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: 1124 • ACR Convergence 2023

    A Double-blind, Placebo-parallel Controlled Phase III Clinical Study of the Efficacy and Safety of Hemay005 Tablets in Patients with Moderate to Severe Chronic Plaque Psoriasis in China

    Charles Jones1, Jianzhong Zhang2, Lihua Wang3, Xunyi Dai4, Huimin Wang5, Xiadong Bi6, Xinsuo Duan7, Zudong Meng8, Zhongwei Tian9, Aie Xu10, Bin Yang11, Shuping Guo12, Wei Li13, Qingchun Diao14, Hong Fang15, Yongjun Liu16, Juanli Fan17, Min Yan18, Sensen Lin19, Mingfei Zhu20, xianjun Hu20, Jinfeng Lin20 and Mingye Bi21, 1Hemay Pharmaceuticals, Tianjin, China, 2Peking University People’s Hospital, Beijing, China, 3Jinan Central Hospital, Jinan, China, 4Wuxi Second People's Hospital, Wuxi, China, 5Jinzhong First People's Hospital, Jinzhong, China, 6Nanyang First People's Hospital, Nanyang, China, 7Chengde Medical College Affiliated Hospital, Chengde, China, 8Shiyan City People's Hospital, Shiyan, China, 9The First Affiliated Hospital of Xinxiang Medical College, Weihui, China, 10Hangzhou Third People's Hospital, Hangzhou, China, 11Skin Disease Hospital of Southern Medical University, Guangzhou, China, 12The First Hospital of Shanxi Medical University, Taiyuan, China, 13West China Hospital of Sichuan University, Chengdu, China, 14Chongqing Traditional Chinese Medicine Hospital, Chongqing, China, 15The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, 16Qiqihar Traditional Chinese Medicine Hospital, Qiqihar, China, 17Yuncheng Central Hospital, Yuncheng, China, 18Shengli Oilfield Central Hospital, Dongying, China, 19Hangzhou Tigermed, Hangzhou, China, 20Clinical Department, Tianjin Hemay Pharmaceutical Co., Ltd., Tianjin, China, 21Wuxi People's Hospital, Wuxi, China

    Background/Purpose: Hemay005 is an orally active selective PDE4 inhibitor under clinical development for treating chronic inflammatory diseases. Hemay005 significantly inhibits the activation of T lymphocytes,…
  • Abstract Number: 1423 • ACR Convergence 2023

    Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial

    Laura Coates1, Catherine Bakewell2, Majed Khraishi3, Shirley Chen4, Tianming Gao4, Arathi Setty4, Heather Jones5, Sandra Ciecinski4 and Eduardo Mysler6, 1University of Oxford, Oxford, United Kingdom, 2Intermountain Healthcare Medical Group, Salt Lake City, UT, 3Memorial University of Newfoundland, St. John's, NL, Canada, 4AbbVie, Inc., North Chicago, IL, 5AbbVie, Inc., Mettawa, IL, 6Organización Medica de Investigación, Buenos Aires, Argentina

    Background/Purpose: Enthesitis and dactylitis are associated with reduced quality of life and greater impairment in daily activities. In the SELECT-PsA 2 phase 3 trial, the…
  • Abstract Number: 1517 • ACR Convergence 2023

    Comparing Deep Neural Network to Modified Rodnan Skin Score in a Trial for Belumosudil in Systemic Sclerosis Patients

    Baran Gunes1, Lucy Duran Camacho1, Shawn Cowper2, Gauri Panse2, Elizabeth Bundschuh3, Alyssa Williams4, Nicolas Page5, Mary Karns6, Kathleen Aren6, Niki Pradhan7, Elana Bernstein8, Sarah Fantus9, Elizabeth Volkmann10, Heather Bukiri10, Chase Correia11, Francis Wilson1, Seamus Mawe12, J. Matthew Mahoney13, Monique Hinchcliff14 and Rui Wang15, 1Yale University School of Medicine, New Haven, CT, 2Yale School of Medicine - Dermatopathology, New Haven, CT, 3Yale University School of Medicine, New York, NY, 4Yale University School of Medicine, Winchester, MA, 5Yale University School of Medicine, Salem, CT, 6Northwestern University Division of Rheumatology, Chicago, IL, 7Columbia University Irving Medical Center, New York, NY, 8Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 9Kansas City Physician Partners- Center for Rheumatic Disease, Kansas City, MO, 10University of California Los Angeles, Los Angeles, CA, 11Riverside Medical Group, Hampton, VA, 12The Jackson Laboratory, Bar Harbor, ME, 13Jackson Laboratory, Bar Harbor, ME, 14Yale School of Medicine, Westport, CT, 15Sanofi, Cambridge, MA

    Background/Purpose: We previously published a proof-of-principle study demonstrating the potential utility of computer vision (Deep Neural Network/DNN) methods applied to stained skin biopsy sections from…
  • Abstract Number: 1992 • ACR Convergence 2023

    Association Between Knee Osteoarthritis Pain and Concomitant Drug Use: A Post-hoc Analysis of Two Phase 3 Clinical Trials

    Claire Miller1, Matthew Baker2, Peter Alexandersen3, Alejandro Mondragón1, Ida Sofie Adrian1, Morten Karsdal4, Jeppe Andersen5 and Asger Bihlet1, 1NBCD, Soeborg, Denmark, 2Stanford University, Menlo Park, CA, 3Sanos Clinics, Gandrup, Denmark, 4Nordic Bioscience, Herlev, Denmark, 5Sanos Group, Soeborg, Denmark

    Background/Purpose: Patients with knee osteoarthritis are often overweight and suffer from comorbidities, which are frequently treated pharmacologically. Our understanding of the potential disease-modifying and/or symptom-modifying…
  • Abstract Number: 2249 • ACR Convergence 2023

    Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies

    Dafna Gladman1, Laura Coates2, Maarten de Wit3, Alexis R Ogdie4, Ana-Maria Orbai5, Barbara Ink6, Vanessa Taieb7, Jérémy Lambert8 and Laure Gossec9, 1Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2University of Oxford, Oxford, United Kingdom, 3Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, 4University of Pennsylvania, Philadelphia, PA, 5Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 6UCB Pharma, Slough, United Kingdom, 7UCB Pharma, Colombes, France, 8UCB Pharma, Irigny, France, 9Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France

    Background/Purpose: The PsA Impact of Disease‑12 (PsAID‑12) questionnaire is a patient (pt)-reported outcome measure assessing the impact of PsA on 12 physical, social, and psychological…
  • Abstract Number: 2490 • ACR Convergence 2023

    Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial

    Junna Ye1, Yijun You2, Zhuochao Zhou2, Jingyi Wu2, Fan wang2 and Chengde Yang2, 1Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, 2Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Background/Purpose: Previous clinical trials of mycophenolate mofetil (MMF) in SLE were mainly focused on lupus nephritis (LN) (patients have been diagnosed with LN). In the…
  • Abstract Number: 010 • 2023 Pediatric Rheumatology Symposium

    Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus: A Preliminary Investigation

    Natoshia Cunningham1, Michelle Adler2, Ashley Danguecan3, Mallet Reid2, Samantha Ely4, Mathew Reeves2, Lawrence Ng3, Paris Moaf3, Sarah Mossad3, Tala El Tal3, Luana Flores Pereira3, Deborah Levy3, Linda Hiraki3, Jennifer Stinson3, Sarah Ahola Kohut3, Khalid Abulaban5, Elizabeth Kessler5, Stacy Allen5, Tamar Rubinstein6, Evin Rothschild6, Natalie Rosenwasser7, Kabita Nanda7, Susan Canny7, Emily Smitherman8, Livie Huie8, James Birmingham9, Allison Thompson10, Janel Thompson10, Miranda Moyer10, Emily Nguyen10, Angela Chapson10 and Andrea Knight3, 1Michigan State University, Grand Rapids, MI, 2Michigan State University, East Lansing, 3The Hospital for Sick Children, Toronto, ON, Canada, 4Wayne State University, Michigan State University, Detroit, MI, 5Helen DeVos Children's Hospital, Grand Rapids, MI, 6Children's Hospital at Montefiore, New York, NY, 7Seattle Children's Hospital, Seattle, WA, 8University of Alabama at Birmingham, Birmingham, AL, 9Metro Health, Cleveland, 10Patient Co-Investigative Team

    Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is associated with fatigue, pain, and depressive symptoms that adversely impact health-related quality of life. The Treatment and Education…
  • Abstract Number: 126 • 2023 Pediatric Rheumatology Symposium

    Facilitating Peer-to-Peer Conversations Around Key Clinical Trial Recruitment Barriers in the Limit-JIA Trial Using Low-Fidelity Video Capture

    Melanie Kohlheim1, Eveline Wu2, Laura Schanberg3, Vincent Del Gaizo1, Catherine Lavallee4, Marc Natter5, Katie Clem6, Brian Shakley6 and Kevin Urban7, 1CARRA, Washington, DC, 2UNC Chapel Hill, Chapel Hill, NC, 3Duke University Medical Center, Durham, NC, 4Virginia Tech Carilion School of Medicine, ROANOKE, VA, 5Boston Children's Hospital, Boston, MA, 6LIFT 1428, Llc, Ooltewah, TN, 7Business Coaching for Creatives, New York, NY

    Background/Purpose: The LIMIT-JIA trial aims to study if early abatacept treatment can prevent disease extension in children with recent-onset, uncomplicated, and oligoarticular or limited JIA.…
  • Abstract Number: L06 • ACR Convergence 2022

    Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study

    Maya H. Buch1, Deepak L. Bhatt2, Christina Charles-Schoeman3, Jon T. Giles4, Ted R. Mikuls5, Gary Koch6, Steven Ytterberg7, Edward Nagy8, Hyejin Jo9, Kenneth Kwok9, Carol A. Connell10, Karim R. Masri11 and Arne Yndestad12, 1Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 2Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 3Division of Rheumatology, Department of Medicine, University of California, Los Angeles, CA, 4Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 5Division of Rheumatology, University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, NE, 6Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, 7Division of Rheumatology, Mayo Clinic, Rochester, MN, 8Pfizer Ltd, Tadworth, Surrey, United Kingdom, 9Pfizer Inc, New York, NY, 10Pfizer Inc, Groton, CT, 11Pfizer Inc, Collegeville, PA, 12Pfizer Inc, Oslo, Norway

    Background/Purpose: ORAL Surveillance (NCT02092467; a post-authorization safety study of tofacitinib 5 and 10 mg twice daily [BID] vs TNF inhibitors [TNFi]) found higher risk of…
  • Abstract Number: L07 • ACR Convergence 2022

    Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study

    Di Wu1, Jing Li1, Dong Xu1, Li Wang1, Jianmin Fang2, Dan Ross3 and Fengchun Zhang4, 1Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China, Beijing, China, 2Shanghai Tongji Hospital, Tongji University, Shanghai 200065, China School of Life Science and Technology, Tongji University, Shanghai 200092, China, Shanghai, China, 3RemeGen Co., San Diego, CA, 4Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, Beijing, China

    Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…
  • Abstract Number: L14 • ACR Convergence 2022

    Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

    Xenofon Baraliakos1, Atul Deodhar2, Désirée van der Heijde3, Marina Magrey4, Walter Maksymowych5, Tetsuya Tomita6, Huji Xu7, Marga Oortgiesen8, Ute Massow9, Carmen Fleurinck10, Alicia M Ellis8, Tom Vaux11, Julie Shepherd-Smith11, Alexander Marten9 and Lianne S Gensler12, 1Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, 2Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, US, Richfield, OH, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6Graduate School of Health Science, Morinomiya University of Medical Science, Osaka City, Osaka City, Osaka, Japan, 7Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China (People's Republic), 8UCB Pharma, Morrisvile, NC, 9UCB Pharma, Monheim am Rhein, Nordrhein-Westfalen, Germany, 10UCB Pharma, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 11UCB Pharma, Slough, United Kingdom, 12Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL‑17A. In the phase 3 BE MOBILE 1 and 2…
  • Abstract Number: L02 • ACR Convergence 2022

    Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study

    Christopher Ritchlin1, Laura Coates2, Iain McInnes3, Philip J. Mease4, Joseph Merola5, Yoshiya Tanaka6, Akihiko Asahina7, Laure Gossec8, Alice Gottlieb9, Diamant Thaci10, Barbara Ink11, Deepak Assudani11, Rajan Bajracharya11, Vish Shende11, Jason Coarse12 and Robert Landewé13, 1University of Rochester Medical Center, Rochester, NY, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, 3College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 4Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 5Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 6University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 7Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, 8Sorbonne Universités, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière, Rheumatology Department, Paris, France, Paris, France, 9Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 11UCB Pharma, Slough, United Kingdom, 12UCB Pharma, Raleigh, NC, 13Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuyderland MC, Heerlen, Netherlands

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy in joints and…
  • Abstract Number: 0281 • ACR Convergence 2022

    Clinical Outcomes of Filgotinib in Patients with RA Aged ≥65 Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical Trials and Ongoing Long-Term Extensions

    Maya Buch1, BERNARD COMBE2, Jose A Gomez-Puerta3, Roberto Felice Caporali4, jacques-eric gottenberg5, Paul Van Hoek6, Vijay Rajendran7, Pieter-Jan Stiers6, Katrien Van Beneden6, Daniel Aletaha8, Gerd Burmester9, Rene Westhovens10 and Yoshiya Tanaka11, 1University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 2Montpellier University, Montpellier, France, 3Hospital Clínic de Barcelona, Barcelona, Spain, 4University of Milan, Milano, Italy, 5Strasbourg University Hospital, Strasbourg, France, 6Galapagos NV, Mechelen, Belgium, 7Galapagos NV, Gent, Belgium, 8Medical University Vienna, Wien, Austria, 9Charité University Medicine Berlin, Berlin, Germany, 10University Hospitals Leuven, Leuven, Belgium, 11University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan

    Background/Purpose: Filgotinib (FIL) is a Janus kinase 1 preferential inhibitor approved for the treatment of moderate to severe active RA.1 It was previously reported that…
  • Abstract Number: 0359 • ACR Convergence 2022

    Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets

    Ronald Van Vollenhoven1, Eric F. Morand2, Richard A. Furie3, Ian N. Bruce4, Gabriel Abreu5, Raj Tummala6, Hussein Al-Mossawi7 and Catharina Lindholm8, 1Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, University of Amsterdam, Amsterdam, Netherlands, 2Monash University, Melbourne, Australia, 3Northwell Health, Great Neck, NY, 4The University of Manchester, Manchester, United Kingdom, 5AstraZeneca, Mölndal, Sweden, 6AstraZeneca, Gaithersburg, MD, 7AstraZeneca, Cambridge, United Kingdom, 8AstraZeneca, Gothenburg, Sweden

    Background/Purpose: In patients with SLE, achieving remission is a treat-to-target goal. Remission is associated with lower rates of hospitalization and damage accrual and better quality…
  • Abstract Number: 0525 • ACR Convergence 2022

    Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR ≤20 in the Avacopan ADVOCATE Trial

    David Jayne1, Peter Merkel2, Frank Cortazar3, John Niles4 and Pirow Bekker5, 1University of Cambridge, Cambridge, United Kingdom, 2U of Pennsylvania, Philadelphia, PA, 3St. Peter's Hospital, Albany, NY, 4Harvard, Boston, MA, 5ChemoCentryx, San Juan Capistrano, CA

    Background/Purpose: In the 330-patient ADVOCATE trial of avacopan for the treatment of ANCA-associated vasculitis, in which 81% of patients with ANCA-associated vasculitis had renal involvement,…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology